Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07109414 · ClinicalTrials.gov registry record · Phase 2
Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)
A Phase 2 study of Platinum-resistant Ovarian Cancer, sponsored by Novita Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 380
- Enrollment target
- 6
- Study locations
NCT07109414: Active Phase 2 study of Platinum-resistant Ovarian Cancer, sponsored by Novita Pharmaceuticals.
NCT07109414 is a Phase 2 study of Platinum-resistant Ovarian Cancer that is active but no longer recruiting, run by Novita Pharmaceuticals. The registered enrollment target is 380 participants, above the 164-participant average among 17 other Platinum-resistant Ovarian Cancer trials with a reported enrollment target (132% higher). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07109414, a Phase 2 study of Platinum-resistant Ovarian Cancer, is active but no longer recruiting, sponsored by Novita Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 380 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of the study is to identify the optimal dose level of NP-G2-044 in combination with standard of care (SOC) pegylated liposomal doxorubicin (PLD), and to compare the efficacy and safety of NP-G2-044+PLD vs. PLD alone in participants with platinum-resistant ovarian cancer (PROC).
Primary Outcome
The safety and tolerability of NP-G2-044 monotherapy with BID dosing and in combination with PLD will be evaluated
Conditions Studied
Interventions
- DRUG PLD
- DRUG NP-G2-044
Study Locations (6)
Arizona
- HonorHealth Cancer Care - Phoenix
Louisiana
- Trials365 - Shreveport
New Mexico
- Optimum Clinical Research Group, LLC - Albuquerque
Pennsylvania
- University of Pennsylvania Health System, Perelman Center for Advanced Medicine - Philadelphia
Utah
- Utah Cancer Specialists - Salt Lake City
Wisconsin
- University Of Wisconsin Carbone Cancer Center - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 380 participants |
| Start Date | 2025-12-29 |
| Est. Completion | 2029-10-24 |
| Phase | Phase 2 |
What the registry record for NCT07109414 still lists
NCT07109414 is an interventional study that assigns participants to a tested intervention. The registered 380 participants enrollment target is mid-sized for trials with a published cap, above the 164-participant average among 17 other Platinum-resistant Ovarian Cancer trials with a reported enrollment target (132% higher).
The record links to 1 condition, with Platinum-resistant Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which PLD is the first listed.
NCT07109414 lists 6 locations in 6 states (Arizona, Louisiana, New Mexico).
Frequently Asked Questions
What is clinical trial NCT07109414 about?
NCT07109414 is a clinical study titled "Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)". The purpose of the study is to identify the optimal dose level of NP-G2-044 in combination with standard of care (SOC) pegylated liposomal doxorubicin (PLD), and to compare the efficacy and safety of NP-G2-044+PLD vs. PLD alone in participants with platinum-resistant ovarian cancer (PROC).
What is the current status of trial NCT07109414?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 380 participants. The study started on 2025-12-29. Estimated completion is 2029-10-24.
What conditions does trial NCT07109414 study?
This clinical trial studies the following conditions: Platinum-resistant Ovarian Cancer.
What interventions are being tested in trial NCT07109414?
The interventions under investigation include: PLD (DRUG), NP-G2-044 (DRUG).
Who is sponsoring clinical trial NCT07109414?
This trial is sponsored by Novita Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07109414 being conducted?
This trial has 6 study locations across Arizona, Louisiana, New Mexico, Pennsylvania, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Platinum-resistant Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07109414's enrollment target sits among peer trials
380 3rd of 17 higher than 15 of 17 other Platinum-resistant Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Platinum-resistant Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
RECRUITING · Phase 2
-
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer
RECRUITING · Phase 2
-
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
RECRUITING · Phase 1
-
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
RECRUITING · Phase 1
-
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04560673 · 380 participants · Phase 2
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
- NCT04777357 · 380 participants · Phase 3
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
- NCT04821154 · 380 participants
Persona Revision Knee System Outcomes
- NCT05102019 · 380 participants · NA
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI